• Phase 2 clinical trial for ATH434 commences in New Zealand and patient enrolment begins
• Regulatory approval from the U.K. and Italian regulatory agencies to proceed with the Phase 2 trial
• A$4.1 million R&D Tax Incentive Scheme refund
• Cash balance on 30 June 2022 of A$34.8M

MELBOURNE, Australia and SAN FRANCISCO, July 22, 2022 /PRNewswire/...